PTC Therapeutics, Inc.
PTCT
株式のランク
#3333
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the... PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
株価
$62.83
最終同期: 2026-10-20
時価総額
$5.24B
変化（1日）
2.11%
変化（1年）
-6.46%
国
US
取引 PTC Therapeutics, Inc. (PTCT)
カテゴリー
Healthcare
PTC Therapeutics, Inc.（PTCT）の収益
Jun 2026 時点の収益 TTM: $1.01B
PTC Therapeutics, Inc. の最新の財務報告によると、現在の収益 (TTM) は $1.01B です。2023 年には $937.82M の収益があり、これは 2022 年の $698.80M と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
PTC Therapeutics, Inc. の収益履歴（2011 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $1.01B | 25.03% |
| 2024 | $806.78M | -13.97% |
| 2023 | $937.82M | 34.20% |
| 2022 | $698.80M | 29.75% |
| 2021 | $538.59M | 41.45% |
| 2020 | $380.77M | 24.04% |
| 2019 | $306.98M | 15.96% |
| 2018 | $264.73M | 36.19% |
| 2017 | $194.39M | 135.04% |
| 2016 | $82.71M | 124.95% |
| 2015 | $36.77M | 60.11% |
| 2014 | $22.96M | -26.70% |
| 2013 | $31.33M | 8.85% |
| 2012 | $28.78M | -70.92% |
| 2011 | $98.96M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | 1,151.47% |
US
|
|
| $2.23B | 120.87% |
US
|
|
| $15.74B | 1,460.77% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 496.90% |
NL
|
